Maxim Group reissued their hold rating on shares of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) in a research report report published on Monday.

“Delmar announced news of another Phase II trial (biomarker driven), N=20-30 in newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM). The trial will be funded by Guangxi Wuzhou Pharmaceutical Group Co. (private). Management states that data is expected 9-15 months from the time the trial begins.”,” Maxim Group’s analyst commented.

A number of other equities research analysts have also recently issued reports on the stock. HC Wainwright reiterated a buy rating and set a $12.00 target price on shares of DelMar Pharmaceuticals in a research report on Tuesday, May 30th. Dawson James restated a buy rating on shares of DelMar Pharmaceuticals in a research report on Tuesday, August 8th.

DelMar Pharmaceuticals (NASDAQ DMPI) opened at 1.17 on Monday. The firm’s market capitalization is $15.75 million. DelMar Pharmaceuticals has a 1-year low of $1.13 and a 1-year high of $6.95. The firm’s 50-day moving average is $1.51 and its 200-day moving average is $2.55.

COPYRIGHT VIOLATION NOTICE: “DelMar Pharmaceuticals’ (DMPI) “Hold” Rating Reaffirmed at Maxim Group” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at

A hedge fund recently bought a new stake in DelMar Pharmaceuticals stock. Franklin Resources Inc. bought a new stake in DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 1,076,923 shares of the company’s stock, valued at approximately $2,477,000. Institutional investors own 13.84% of the company’s stock.

About DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.